Clinical trial · no report yet · Phase 2
BRICKET
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- NCT06578559 ↗
- Active, not recruiting
- Gruppo Oncologico del Nord-Ovest
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 11 |
The trial
ClinicalTrials.gov- Official title
- Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Cetuximab; Encorafenib
- Arms
- Encorafenib + Cetuximab · Experimental
- Enrollment
- 16 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Gruppo Oncologico del Nord-Ovest with Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
- Start
- Jul 23, 2024
- Primary completion
- May 12, 2026
- Results posted
- No
- Registry record
- NCT06578559 · updated Sep 9, 2026